List your company

Glytec

Provider of AI-powered, cloud-based inpatient glycemic management software and clinical decision support systems for health systems and health plans.

Visit website

About Glytec

Provider of AI-powered, cloud-based inpatient glycemic management software and clinical decision support systems for health systems and health plans.

Industries served

Products

  • Glucommander

    Patient Engagement & Care

    View product

    FDA-cleared Class II Software as a Medical Device (SaMD) that provides algorithm-based insulin dosing recommendations for intravenous (IV) and subcutaneous (SubQ) delivery.

What customers say

  • Riverside Healthcare implemented Glucommander to replace paper insulin protocols and integrated it with Epic. Glytec reports that Riverside’s internal retrospective study found an 18% shorter Critical Care Unit stay and…

    Case study

Security and compliance

As reported by Glytec. Ask for audit reports before you buy.

  • HITRUST CSFCertified
  • HIPAACertified
  • Cloud-based infrastructure
  • Enterprise-grade security
  • Automatic security updates
  • Business continuity support

Is this your company?

Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.

Claim Glytec

Latest updates from Glytec

Product launch

Glytec Launches GlytecOne Population Health Solution for Health Plans

Glytec has launched GlytecOne for Health Plans and Value-Based Care Leaders, a population health solution designed to provide glycemic intelligence to health plans and value-based care organizations. The platform aggregates inpatient glycemic data across hospital networks to help leaders identify avoidable cost patterns, monitor hospital performance on glycemic metrics, and improve quality scores like HEDIS and Star Ratings. By connecting inpatient glycemic performance to longitudinal member health information, the tool aims to support care coordination, reduce preventable hypoglycemic and hyperglycemic events, and decrease readmission rates for diabetic populations.